{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:56:47Z","timestamp":1791896207683,"version":"4.3.4"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T00:00:00Z","timestamp":1653004800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","award":["201506220185"],"award-info":[{"award-number":["201506220185"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"Commission of the European Communities","doi-asserted-by":"publisher","award":["602666"],"award-info":[{"award-number":["602666"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal for Parasitology: Drugs and Drug Resistance"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.ijpddr.2022.05.004","type":"journal-article","created":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T12:57:19Z","timestamp":1653569839000},"page":"47-55","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["3-nitroimidazo[1,2-b]pyridazine as a novel scaffold for antiparasitics with sub-nanomolar anti-Giardia lamblia activity"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7035-8807","authenticated-orcid":false,"given":"Yang","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1691-503X","authenticated-orcid":false,"given":"Stefan","family":"Kunz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Siderius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2324-9509","authenticated-orcid":false,"given":"Louis","family":"Maes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4870-3202","authenticated-orcid":false,"given":"Guy","family":"Caljon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0622-2128","authenticated-orcid":false,"given":"Andrew","family":"Hemphill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert Jan","family":"Sterk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Leurs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijpddr.2022.05.004_bib1","doi-asserted-by":"crossref","first-page":"7636","DOI":"10.1021\/acs.jmedchem.7b00143","article-title":"Nitroimidazoles: molecular fireworks that combat a broad spectrum of infectious diseases","volume":"60","author":"Ang","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ijpddr.2022.05.004_bib2","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.mimet.2007.07.014","article-title":"A new quantitative in vitro microculture method for Giardia duodenalis trophozoites","volume":"71","author":"B\u00e9n\u00e9r\u00e9","year":"2007","journal-title":"J. Microbiol. Methods"},{"key":"10.1016\/j.ijpddr.2022.05.004_bib3","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1177\/1087057114549735","article-title":"Fragment-based screening in tandem with phenotypic screening provides novel antiparasitic hits","volume":"20","author":"Blaazer","year":"2014","journal-title":"J. Biomol. Screen"},{"key":"10.1016\/j.ijpddr.2022.05.004_bib4","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1021\/acs.jmedchem.7b01670","article-title":"Targeting a subpocket in trypanosoma brucei phosphodiesterase B1 (TbrPDEB1) enables the structure-based discovery of selective inhibitors with trypanocidal activity","volume":"61","author":"Blaazer","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ijpddr.2022.05.004_bib5","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4269\/ajtmh.15-0007","article-title":"Antimalarial drug resistance: literature review and activities and findings of the ICEMR network","volume":"93","author":"Cui","year":"2015","journal-title":"Am. Soc. Trop. Med. Hyg."},{"key":"10.1016\/j.ijpddr.2022.05.004_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2020.608030","article-title":"Discovery of diaryl ether substituted tetrahydrophthalazinones as TbrPDEB1 inhibitors following structure-based virtual screening","author":"de Heuvel","year":"2021","journal-title":"Front. Chem."},{"key":"10.1016\/j.ijpddr.2022.05.004_bib7","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3390\/tropicalmed5010014","article-title":"The drugs of sleeping sickness: their mechanisms of action and resistance, and a brief history","volume":"5","author":"de Koning","year":"2020","journal-title":"Trop. Med. Infect. Dis."},{"key":"10.1016\/j.ijpddr.2022.05.004_bib8","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1093\/infdis\/jir857","article-title":"Pharmacological validation of trypanosoma brucei phosphodiesterases as novel drug targets","volume":"206","author":"de Koning","year":"2012","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ijpddr.2022.05.004_bib9","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1021\/jm801490z","article-title":"Synthesis and antiplasmodial activity of aminoalkylamino-substituted neocryptolepine derivatives","volume":"52","author":"El Sayed","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ijpddr.2022.05.004_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113867","article-title":"Imidazo[1,2-b]pyridazine as privileged scaffold in medicinal chemistry: an extensive review","volume":"226","author":"Garrido","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ijpddr.2022.05.004_bib11","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1093\/jac\/dku422","article-title":"Nitroimidazo-oxazole compound DNDI-VL-2098: an orally effective preclinical drug candidate for the treatment of visceral leishmaniasis","volume":"70","author":"Gupta","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ijpddr.2022.05.004_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pntd.0005424","article-title":"The global burden of disease study 2013: what does it mean for the NTDs?","volume":"11","author":"Herricks","year":"2017","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ijpddr.2022.05.004_bib13","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S1359-6446(05)03622-6","article-title":"Keynote review: phosphodiesterase-4 as a therapeutic target","volume":"10","author":"Houslay","year":"2005","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ijpddr.2022.05.004_bib14","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1021\/cb501004q","article-title":"Identification of potent phosphodiesterase inhibitors that demonstrate cyclic nucleotide-dependent functions in apicomplexan parasites","volume":"10","author":"Howard","year":"2015","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ijpddr.2022.05.004_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pntd.0005891","article-title":"The single cyclic nucleotide-specific phosphodiesterase of the intestinal parasite Giardia lamblia represents a potential drug target","volume":"11","author":"Kunz","year":"2017","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ijpddr.2022.05.004_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005891","article-title":"The single cyclic nucleotide-specific phosphodiesterase of the intestinal parasite Giardia lamblia represents a potential drug target","volume":"11","author":"Kunz","year":"2017","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ijpddr.2022.05.004_bib17","doi-asserted-by":"crossref","first-page":"6412","DOI":"10.1111\/j.1742-4658.2005.05039.x","article-title":"A FYVE-containing unusual cyclic nucleotide phosphodiesterase from Trypanosoma cruzi","volume":"272","author":"Kunz","year":"2005","journal-title":"FEBS J."},{"key":"10.1016\/j.ijpddr.2022.05.004_bib18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(96)00423-1","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"23","author":"Lipinski","year":"1997","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijpddr.2022.05.004_bib19","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1021\/jm040217u","article-title":"The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases","volume":"48","author":"Manallack","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ijpddr.2022.05.004_bib20","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrd4228","article-title":"Advances in targeting cyclic nucleotide phosphodiesterases","volume":"13","author":"Maurice","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ijpddr.2022.05.004_bib21","first-page":"248","article-title":"The rule of five should not impede anti-parasitic drug development","volume":"7","author":"McKerrow","year":"2017","journal-title":"Int. J. Parasitol.: Drugs Drug Resist."},{"key":"10.1016\/j.ijpddr.2022.05.004_bib22","doi-asserted-by":"crossref","DOI":"10.1097\/QCO.0000000000000668","article-title":"Giardiasis treatment: an update with a focus on refractory disease","volume":"33","author":"M\u00f8rch","year":"2020","journal-title":"Curr. Opin. Infect. Dis."},{"key":"10.1016\/j.ijpddr.2022.05.004_bib23","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1017\/S0031182020000657","article-title":"Comparative proteomics of three Giardia lamblia strains: investigation of antigenic variation in the post-genomic era","volume":"147","author":"M\u00fcller","year":"2020","journal-title":"Parasitology"},{"key":"10.1016\/j.ijpddr.2022.05.004_bib24","series-title":"International Review of Cell and Molecular Biology","first-page":"359","article-title":"New approaches for the identification of drug targets in Protozoan parasites","author":"M\u00fcller","year":"2013"},{"key":"10.1016\/j.ijpddr.2022.05.004_bib25","doi-asserted-by":"crossref","DOI":"10.1002\/mbo3.904","article-title":"Nitroreductases of bacterial origin in Giardia lamblia: potential role in detoxification of xenobiotics","volume":"8","author":"M\u00fcller","year":"2019","journal-title":"Microbiologyopen"},{"key":"10.1016\/j.ijpddr.2022.05.004_bib26","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.cmi.2015.04.019","article-title":"Increased incidence of nitroimidazole-refractory giardiasis at the hospital for tropical diseases, london: 2008\u20132013","volume":"21","author":"Nabarro","year":"2015","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.ijpddr.2022.05.004_bib28","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1096\/fj.06-6818com","article-title":"The Trypanosoma brucei cAMP phosphodiesterases TbrPDEBl and TbrPDEB2: flagellar enzymes that are essential for parasite virulence","volume":"21","author":"Oberholzer","year":"2007","journal-title":"Faseb. J."},{"key":"10.1016\/j.ijpddr.2022.05.004_bib29","doi-asserted-by":"crossref","first-page":"5120","DOI":"10.1016\/j.bmc.2015.04.017","article-title":"From hybrid compounds to targeted drug delivery in antimalarial therapy","volume":"23","author":"Oliveira","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ijpddr.2022.05.004_bib30","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.pt.2014.04.003","article-title":"Nitro drugs for the treatment of trypanosomatid diseases: past, present, and future prospects","volume":"30","author":"Patterson","year":"2014","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.ijpddr.2022.05.004_bib31","first-page":"7","article-title":"Current trends in the pharmacological management of Chagas disease","volume":"12","author":"Ribeiro","year":"2020","journal-title":"Int. J. Parasitol.: Drugs Drug Resist."},{"key":"10.1016\/j.ijpddr.2022.05.004_bib32","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1128\/AAC.00313-10","article-title":"Chemical validation of phosphodiesterase C as a chemotherapeutic target in trypanosoma cruzi, the etiological agent of Chagas' disease","volume":"54","author":"Sharon","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2022.05.004_bib33","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0162-3109(00)00185-5","article-title":"Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors","volume":"47","author":"Souness","year":"2000","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.ijpddr.2022.05.004_bib34","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/slct.201601353","article-title":"Drugs against neurodegenerative diseases: design and synthesis of 6-Amino\u2013substituted imidazo[1,2-b]pyridazines as acetylcholinesterase inhibitors","volume":"2","author":"Sridhar","year":"2017","journal-title":"ChemistrySelect"},{"key":"10.1016\/j.ijpddr.2022.05.004_bib35","series-title":"Piperidine-pyridazones and Phthalazones as PDE4 Inhibitors","author":"Sterk","year":"2004"},{"key":"10.1016\/j.ijpddr.2022.05.004_bib36","series-title":"Pyridazinone-derivatives as PDE4 Inhibitors","author":"Sterk","year":"2004"},{"key":"10.1016\/j.ijpddr.2022.05.004_bib37","series-title":"Pharmacology, Clinical Efficacy, and Tolerability of Phosphodiesterase-4 Inhibitors: Impact of Human Pharmacokinetics, Phosphodiesterases as Drug Targets","author":"Tenor","year":"2011"},{"key":"10.1016\/j.ijpddr.2022.05.004_bib38","series-title":"6-substituted 3-Nitroimidazo(1,2-B)pyridazines and Method of Preparing Same","author":"Tomcufcik","year":"1974"},{"key":"10.1016\/j.ijpddr.2022.05.004_bib39","doi-asserted-by":"crossref","first-page":"11802","DOI":"10.1016\/j.tet.2008.08.116","article-title":"Synthesis of 6-methyl-6H-indolo[3,2-c]isoquinoline and 6-methyl-6H-indolo[2,3-c]isoquinoline: two new unnatural isoquinoline isomers of the cryptolepine series","volume":"64","author":"van Baelen","year":"2008","journal-title":"Tetrahedron"},{"key":"10.1016\/j.ijpddr.2022.05.004_bib40","first-page":"2523","article-title":"Novel selective phosphodiesterase (PDE4) inhibitors. 4. Resolution, absolute configuration, and PDE4 inhibitory activity of cis-tetra- and cis-hexahydrophthalazinones","volume":"45","author":"van der Mey","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ijpddr.2022.05.004_bib41","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1021\/jm010837k","article-title":"Novel selective PDE4 inhibitors. 1. Synthesis, Structure\u2212Activity relationships, and molecular modeling of 4-(3,4-dimethoxyphenyl)-2H-phthalazin-1-ones and analogues","volume":"44","author":"van der Mey","year":"2001","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ijpddr.2022.05.004_bib42","first-page":"41","article-title":"Drug resistance in vectorborne parasites: multiple actors and scenarios for an evolutionary arms race","volume":"38","author":"Vanaerschot","year":"2014","journal-title":"FEMS (Fed. Eur. Microbiol. Soc.) Microbiol. Rev."},{"key":"10.1016\/j.ijpddr.2022.05.004_bib43","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.bmc.2016.02.032","article-title":"Synthesis and evaluation of analogs of the phenylpyridazinone NPD-001 as potent trypanosomal TbrPDEB1 phosphodiesterase inhibitors and in vitro trypanocidals","volume":"24","author":"Veerman","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ijpddr.2022.05.004_bib44","doi-asserted-by":"crossref","first-page":"5241","DOI":"10.1016\/j.bmc.2014.08.005","article-title":"From human immunodeficiency virus non-nucleoside reverse transcriptase inhibitors to potent and selective antitrypanosomal compounds","volume":"22","author":"Venkatraj","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ijpddr.2022.05.004_bib27","series-title":"No Time to Wait: Securing the Future from Drug-Resistant Infections","year":"2019"}],"container-title":["International Journal for Parasitology: Drugs and Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211320722000100?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211320722000100?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:51:56Z","timestamp":1761922316000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211320722000100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":44,"alternative-id":["S2211320722000100"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpddr.2022.05.004","relation":{},"ISSN":["2211-3207"],"issn-type":[{"value":"2211-3207","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"3-nitroimidazo[1,2-b]pyridazine as a novel scaffold for antiparasitics with sub-nanomolar anti-Giardia lamblia activity","name":"articletitle","label":"Article Title"},{"value":"International Journal for Parasitology: Drugs and Drug Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijpddr.2022.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd on behalf of Australian Society for Parasitology.","name":"copyright","label":"Copyright"}]}}